secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-208137
Event type: regulatory
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics receives FDA CRL for avasopasem; cuts workforce by 70% to extend cash runway
--------------------------------------------------------------------------------

- FDA issued CRL for avasopasem NDA; Phase 3 ROMAN + GT-201 data not sufficiently persuasive; additional trial required.
- Workforce reduced by 22 employees (~70%); estimated restructuring charges of $2.0M to $2.5M.
- Preliminary cash, equivalents, and short-term investments of $38.8M as of June 30, 2023; cash runway extended into Q2 2024.
- Mark Bachleda, Chief Commercial Officer, position eliminated in workforce reduction.
- Company intends to request Type A FDA meeting and explore strategic alternatives including partnering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523208137/0001193125-23-208137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523208137/d538959d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-208137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer